Phototherapy including photothermal therapy (PTT) and photodynamic therapy (PDT) is widely used for cancer treatment because of its non-invasiveness, spatiotemporal controllability, and low side effects. However, the PTT and PDT capabilities of photosensitizers (PSs) compete so it's still a crucial challenge to simultaneously enhance the PDT and PTT capabilities of PSs. In this work, donor-π-acceptor (D-π-A)-based boron dipyrromethene (BODIPY) dyes were developed via molecular engineering and applied for enhanced phototherapy of triple-negative breast cancer. With thiophene engineering and iodine addition, D-π-A BDP dyes possessed a low energy gap between the singlet and triplet states (ΔES1-T1). After the BDP dyes were prepared into nanoparticles (NPs), the BDP4 NPs showed increased generation of type I and II reactive oxygen species (ROS) as well as a high photothermal conversion efficiency (44 %). Furthermore, folate (FA)-modified BDP4 NPs achieved high tumor targeting via near-infrared bioimaging. With these advantages, BDP4 NPs with FA achieved total tumor eradication and tumor metastasis suppression via a single injection and 808 nm laser irradiation. This work provided a rational design of D-π-A PSs for simultaneously enhancing their photodynamic and photothermal performance, achieving efficient cancer therapy.
Keywords: Boron dipyrromethene; D-π-A; Photodynamic therapy; Photothermal therapy; Tumor targeting.
Copyright © 2025 Elsevier Inc. All rights reserved.